SLC5A2 and type 2 diabetes mellitus: To date, the majority of cardiac magnetic resonance imaging studies assessing the effects of SGLT2 inhibitors on cardiac structure and function in patients with T2DM showed a reduction in left ventricular (LV) volume and mass and an improvement in indices of diastolic function, but little change in LV ejection fraction (Matsutani et al., 2018; Verma et al., 2019; Hwang et al., 2020; Lee et al., 2021).